MP1032 Treatment in Patients With Moderate to Severe COVID-19
Status:
Not yet recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of MP1032 with standard of
care (SoC) verses placebo with SoC in hospitalized adults participants with moderate to
severe coronavirus disease 2019 (COVID-19).